Is Facebook the Place for FDA? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Is Facebook the Place for FDA?
Social media tools have taken over many aspects of our lives, now including regulatory info.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 14

If you haven't seen it yet, FDA has a Facebook page. In fact, as of this writing, the agency had nearly 4000 "friends" and more than 150 related links on its page ( http://www.facebook.com/fda/). Among the agency's "favorite pages" are the CDC, the White House, Aids.gov, and Healthcare.gov. FDA and the US government as a whole are trying to be more transparent and open about the way they do things, but it's unclear whether a Facebook page is the right approach, or garnering the right audience.

For example, one friend of the FDA page located outside the US asks on the agency's Facebook wall, why he can't send a carton of cigarettes to his friend in New Jersey for his birthday. Others have used the site to post negative comments about regulatory policies and initiatives.

The agency has online supporters, too. One friend comments that people would not be able to trust drugs, food, cosmetics, medical devices, and more if it weren't for FDA's activities. He writes, "I would love to see how this country would operate with no FDA and no regulations." Others use the page to ask questions about drug approvals or to lobby for their own pharma or healthcare causes.

To date, FDA does not seem to be responding to these comments or questions. Instead, the agency uses the page to make announcements about new initiatives, to post press releases, and so forth. FDA also has a more serious LinkedIn page and a Twitter account, the latter of which it has used to release recall alerts to the public rather quickly. Pharmaceutical Technology would like to hear your thoughts on FDA's use of social media tools and how you use them in your day-to-day work.

Angie Drakulich is the managing editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here